

Clinical trials of SCH 530348

TrialResults-center www.trialresultscenter.org

1 percutaneous coronary intervention

| Trial | Treatments | Patients | Trials design and methods |
|---|--|--|---------------------------------|
| SCH 530348 vs placebo | | | |
| TRA-PCI , 2009 [NCT00132912] n=NA follow-up: | SCH 530348 3 doses: 10mg, 20mg and 40mg versus placebo | patients aged 45 years or older and undergoing non-urgent PCI or coronary angiography with planned PCI | Parallel groups double-blind |

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>

References

TRA-PCI, 2009:

Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009 Mar 14;373:919-28 [[19286091](#)] [10.1016/S0140-6736\(09\)60230-0](https://doi.org/10.1016/S0140-6736(09)60230-0)